Chemical: Drug
hydrocortisone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.



PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for hydrocortisone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
VIP No Clinical Annotations available No Variant Annotations available
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • 11beta-Hydroxycortisone
  • 17alpha-Hydroxycorticosterone
  • Anti-inflammatory hormone
  • Dihydrocostisone
  • Hidrocortisona [INN-Spanish]
  • Hydrocorticosterone
  • Hydrocortisone Acetate
  • Hydrocortisone Base
  • Hydrocortisone Butyrate
  • Hydrocortisone Sodium Phosphate
  • Hydrocortisone Valerate
  • Hydrocortisone alcohol
  • Hydrocortisone free alcohol
  • Hydrocortisonum [INN-Latin]
  • Hydroxycortisone
  • Idrocortisone [DCIT]
Trade Names
  • Acticort
  • Aeroseb HC
  • Aeroseb-HC
  • Ala-Scalp
  • Ala-cort
  • Alacort
  • Algicirtis
  • Alphaderm
  • Amberin
  • Anflam
  • Anusol HC
  • Aquacort
  • Aquanil HC
  • Balneol-hc
  • Barseb HC
  • Basan-Corti
  • Beta-hc
  • CaldeCORT Spray
  • Cetacort
  • Clear aid
  • Cleiton
  • Cobadex
  • Colocort
  • Compound F
  • Cort-Dome
  • Cort-Quin
  • Cortaid
  • Cortanal
  • Cortef
  • Cortef Acetate
  • Cortenema
  • Cortesal
  • Corticreme
  • Cortifan
  • Cortifoam
  • Cortiment
  • Cortisol
  • Cortisol alcohol
  • Cortisolonum
  • Cortisporin
  • Cortisporin Otico
  • Cortispray
  • Cortolotion
  • Cortonema
  • Cortoxide
  • Cortril
  • Cremesone
  • Cremicort-H
  • Cutisol
  • Delacort
  • Derm-Aid
  • Dermacort
  • Dermaspray
  • Dermil
  • Dermocortal
  • Dermolate
  • Dioderm
  • Dome-cort
  • Domolene-HC
  • Dricort
  • Drotic
  • EF corlin
  • Efcorbin
  • Efcortelan
  • Efcortelin
  • Eldecort
  • Eldercort
  • Epicort
  • Epiderm H
  • Esiderm H
  • Evacort
  • Ficortril
  • Fiocortril
  • Flexicort
  • Foille Insetti
  • Genacort
  • Glycort
  • Gyno-Cortisone
  • H-Cort
  • Heb Cort
  • Heb-Cort
  • Hemsol-HC
  • Hi-cor
  • Hidalone
  • Hidro-Colisona
  • Hycort
  • Hycortol
  • Hycortole
  • Hydracort
  • Hydrasson
  • Hydro-adreson
  • Hydro-colisona
  • Hydrocort
  • Hydrocortal
  • Hydrocortistab
  • Hydrocortisyl
  • Hydrocortone
  • Hydroskin
  • Hysone
  • Hytisone
  • Hytone
  • Hytone lotion
  • Incortin-H
  • Incortin-hydrogen
  • Kendall's compound F
  • Komed HC
  • Kyypakkaus
  • Lacticare HC
  • Lacticare-HC
  • Lactisona
  • Locoid
  • Locoid Lipocream
  • Lubricort
  • Maintasone
  • Medicort
  • Meusicort
  • Micort-hc
  • Mildison
  • Milliderm
  • Neosporin-H Ear
  • Nogenic HC
  • Nutracort
  • Nystaform-HC
  • Optef
  • Orabase HCA
  • Otalgine
  • Otobiotic
  • Otocort
  • Otosone-F
  • Pandel
  • Pediotic Suspension
  • Penecort
  • Permicort
  • Polcort H
  • Preparation H Hydrocortisone Cream
  • Prepcort
  • Prevex HC
  • Proctocort
  • Proctofoam
  • Protocort
  • Racet
  • Rectoid
  • Reichstein's Substance M
  • Remederm HC
  • Sanatison
  • Scalpicin Capilar
  • Schericur
  • Scheroson F
  • Sigmacort
  • Signef
  • Stie-cort
  • Stiefcorcil
  • Synacort
  • Systral Hydrocort
  • THE
  • Tarcortin
  • Tetrahydro E
  • Tetrahydrocompound E
  • Texacort
  • Texacort lotion 25
  • Thyrotropic-releasing factor
  • Timocort
  • Transderma H
  • Traumaide
  • Uniderm
  • Urocortisone
  • Vioform-Hydrocortisone
  • VoSol HC
  • Vytone
  • Westcort
  • Zenoxone
Brand Mixture Names
  • Actinac Pwr (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
  • Actinac Pws (Allantoin + Butoxyethyl Nicotinate + Chloramphenicol + Hydrocortisone Acetate + Sulfur)
  • Calmurid Hc Crm (Hydrocortisone + Urea)
  • Cortisporin (Bacitracin Zinc + Hydrocortisone + Neomycin Sulfate + Polymyxin B Sulfate)
  • Eye and Wound Powder (Chlorhexidine Hydrochloride + Hydrocortisone Acetate + Penicillin G Procaine + Sulfathiazole)
  • Forte Topical Suspension (Hydrocortisone Acetate + Hydrocortisone Sodium Succinate + Neomycin (Neomycin Sulfate) + Penicillin G Procaine + Polymyxin B Sulfate)
  • Neo-Cortef Eye Ear Dps (Hydrocortisone Acetate + Neomycin Sulfate)
  • Neo-Cortef Eye Ear Drops Sterile Suspension (Hydrocortisone Acetate + Neomycin Sulfate)
  • Neo-Cortef Eye Ear Ont (Hydrocortisone Acetate + Neomycin Sulfate)
  • Ophthocort Ont (Chloramphenicol + Hydrocortisone Acetate + Polymyxin B (Polymyxin B Sulfate))
  • Otizol Hc Liq (Hydrocortisone (Hydrocortisone Acetate) + Lidocaine (Lidocaine Hydrochloride) + Neomycin (Neomycin Sulfate))
  • Proctosedyl Ointment (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
  • Proctosedyl Sup (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
  • Proctosedyl Suppositories (Dibucaine Hydrochloride + Esculin + Framycetin Sulfate + Hydrocortisone)
  • Proctosone Ont (Dibucaine Hydrochloride + Esculin + Hydrocortisone Acetate + Neomycin Sulfate)
  • Proctosone Sup (Dibucaine Hydrochloride + Esculin + Hydrocortisone Acetate + Neomycin Sulfate)
  • Sopamycetin/Hc Ointment (Chloramphenicol + Hydrocortisone Acetate)
  • Sopamycetin/Hc Ont (Chloramphenicol + Hydrocortisone Acetate)
  • Sopamycetin/Hc Susp (Chloramphenicol + Hydrocortisone Acetate)
  • Ti-U-Lac Hc Lotion (Hydrocortisone + Urea)
  • Vioform + Hydrocortisone (Clioquinol + Hydrocortisone)
  • Vioform Hydrocortisone Cream (Clioquinol + Hydrocortisone)
  • Vioform Hydrocortisone Mild (Clioquinol + Hydrocortisone)
  • Vosol Hc (Acetic Acid + Benzethonium Chloride + Hydrocortisone + Propylene Glycol Diacetate)

PharmGKB Accession Id

PA449905

Type(s):

Drug

Description

The main glucocorticoid secreted by the adrenal cortex. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.

Source: Drug Bank

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Also used to treat endocrine (hormonal) disorders (adrenal insufficiency, Addisons disease). It is also used to treat many immune and allergic disorders, such as arthritis, lupus, severe psoriasis, severe asthma, ulcerative colitis, and Crohn's disease.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Hydrocortisone binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In other words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.

Source: Drug Bank

Pharmacology

Hydrocortisone is the most important human glucocorticoid. It is essential for life and regulates or supports a variety of important cardiovascular, metabolic, immunologic and homeostatic functions. Topical hydrocortisone is used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses. Glucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic effects. Glucocorticoids are distinguished from mineralocorticoids and sex steroids by having different receptors, target cells, and effects. Technically, the term corticosteroid refers to both glucocorticoids and mineralocorticoids, but is often used as a synonym for glucocorticoid. Glucocorticoids suppress cell-mediated immunity. They act by inhibiting genes that code for the cytokines IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8 and TNF-alpha, the most important of which is the IL-2. Reduced cytokine production limits T cell proliferation. Glucocorticoids also suppress humoral immunity, causing B cells to express lower amounts of IL-2 and IL-2 receptors. This diminishes both B cell clonal expansion and antibody synthesis. The diminished amounts of IL-2 also leads to fewer T lymphocyte cells being activated.

Source: Drug Bank

Food Interaction

Take with food to reduce irritation. Calcium, phosphorous, potassium, Vitamin A, C, D and zinc needs increased with long term use.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Primarily hepatic via CYP3A4

Source: Drug Bank

Protein Binding

95%

Source: Drug Bank

Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Source: Drug Bank

Half-Life

6-8 hours

Source: Drug Bank

Toxicity

Side effects include inhibition of bone formation, suppression of calcium absorption and delayed wound healing

Source: Drug Bank

Route of Elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Source: Drug Bank

Chemical Properties

Chemical Formula

C21H30O5

Source: Drug Bank

Isomeric SMILES

C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O

Source: OpenEye

Canonical SMILES

C[C@]12C[C@H]

Source: Drug Bank

Average Molecular Weight

362.4599

Source: Drug Bank

Monoisotopic Molecular Weight

362.20932407

Source: Drug Bank

SMILES

[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C

Source: Drug Bank

InChI String

InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1

Source: Drug Bank

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ALOX5 (source: Drug Bank )
ANXA1 (source: Drug Bank )
NOS2 (source: Drug Bank )
NR3C1 (source: Drug Bank )
POMC (source: Drug Bank )
SHBG (source: Drug Bank )

Drug Interactions

Interaction Description
aspirin - hydrocortisone The corticosteroid decreases the effect of salicylates (source: Drug Bank )
aspirin - hydrocortisone The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, acetylsalicylic acid. (source: Drug Bank )
cholestyramine - hydrocortisone Decreases the effect of hydrocortisone (source: Drug Bank )
cholestyramine - hydrocortisone Decreases the effect of hydrocortisone (source: Drug Bank )
colestipol - hydrocortisone Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
colestipol - hydrocortisone Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
fosphenytoin - hydrocortisone The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - acenocoumarol The corticosteroid alters the anticoagulant effect (source: Drug Bank )
hydrocortisone - acenocoumarol The corticosteroid, hydrocortisone, alters the anticoagulant effect, acenocoumarol. (source: Drug Bank )
hydrocortisone - ambenonium The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, ambenonium. (source: Drug Bank )
hydrocortisone - amobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - amobarbital The barbiturate, amobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - anisindione The corticosteroid, hydrocortisone, alters the anticoagulant effect of anisindione. (source: Drug Bank )
hydrocortisone - aprobarbital The barbiturate, aprobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - aspirin The corticosteroid decreases the effect of salicylates (source: Drug Bank )
hydrocortisone - butabarbital The barbiturate, butabarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - butalbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - butalbital The barbiturate, butalbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - butethal The barbiturate, butethal, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - cholestyramine Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
hydrocortisone - cholestyramine Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
hydrocortisone - colestipol Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
hydrocortisone - colestipol Cholestyramine decreases the effect of hydrocortisone (source: Drug Bank )
hydrocortisone - dicumarol The corticosteroid alters the anticoagulant effect (source: Drug Bank )
hydrocortisone - dicumarol The corticosteroid, hydrocortisone, alters the anticoagulant effect of dicumarol. (source: Drug Bank )
hydrocortisone - edrophonium The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank )
hydrocortisone - edrophonium The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, edrophonium. (source: Drug Bank )
hydrocortisone - ethotoin The enzyme inducer, ethotoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - fosphenytoin The enzyme inducer, fosphenytoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - heptabarbital The barbiturate, heptabarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - hexobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - hexobarbital The barbiturate, hexobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - mephenytoin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - mephenytoin The enzyme inducer, mephenytoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - methohexital The barbiturate, methohexital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - methylphenobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - methylphenobarbital The barbiturate, methylphenobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - midodrine Increased arterial pressure (source: Drug Bank )
hydrocortisone - neostigmine The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank )
hydrocortisone - neostigmine The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, neostigmine. (source: Drug Bank )
hydrocortisone - pentobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - pentobarbital The barbiturate, pentobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - phenobarbital The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - phenobarbital The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - phenytoin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - phenytoin The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - primidone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - primidone The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - pyridostigmine The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank )
hydrocortisone - pyridostigmine The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine. (source: Drug Bank )
hydrocortisone - quinidine The barbiturate, quinidine barbiturate, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - rifampin The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank )
hydrocortisone - rifampin The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - salicylate-magnesium The corticosteroid decreases the effect of salicylates (source: Drug Bank )
hydrocortisone - salicylate-sodium The corticosteroid decreases the effect of salicylates (source: Drug Bank )
hydrocortisone - salicylate-sodium The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salicylate-sodium. (source: Drug Bank )
hydrocortisone - salsalate The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, salsalate. (source: Drug Bank )
hydrocortisone - secobarbital The barbiturate, secobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - talbutal The barbiturate, talbutal, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
hydrocortisone - trisalicylate-choline The corticosteroid, hydrocortisone, may decrease the effect of the salicylate, trisalicylate-choline. (source: Drug Bank )
hydrocortisone - warfarin The corticosteroid alters the anticoagulant effect (source: Drug Bank )
hydrocortisone - warfarin The corticosteroid, hydrocortisone, alters the anticoagulant effect of warfarin. (source: Drug Bank )
midodrine - hydrocortisone Increased arterial pressure (source: Drug Bank )
phenobarbital - hydrocortisone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
phenobarbital - hydrocortisone The barbiturate, phenobarbital, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
phenytoin - hydrocortisone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank )
phenytoin - hydrocortisone The enzyme inducer, phenytoin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
primidone - hydrocortisone The barbiturate decreases the effect of the corticosteroid (source: Drug Bank )
primidone - hydrocortisone The barbiturate, primidone, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
pyridostigmine - hydrocortisone The corticosteroid decreases the effect of anticholinesterases (source: Drug Bank )
pyridostigmine - hydrocortisone The corticosteroid, hydrocortisone, may decrease the effect of the anticholinesterase, pyridostigmine. (source: Drug Bank )
rifampin - hydrocortisone The enzyme inducer decreases the effect of the corticosteroid (source: Drug Bank )
rifampin - hydrocortisone The enzyme inducer, rifampin, may decrease the effect of the corticosteroid, hydrocortisone. (source: Drug Bank )
tacrine - hydrocortisone Tacrine and Hydrocortisone may independently exacerbate muscle weakness in myasthenia gravis patients. Monitor for additive muscle weakness effects. (source: Drug Bank )
trastuzumab - hydrocortisone Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to hydrocortisone: 9

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014. Lopez-Lopez Elixabet, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz. European journal of clinical pharmacology. 2014. Naidoo Panjasaram, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for CYP3A5. Pharmacogenetics and genomics. 2012. Lamba Jatinder, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. The pharmacogenomics journal. 2011. Ansari M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hydrocortisone therapy for patients with septic shock. The New England journal of medicine. 2008. Sprung Charles L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proceedings of the National Academy of Sciences of the United States of America. 1998. Bertilsson G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clinical pharmacology and therapeutics. 1997. Madsen H, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0009-0142-01
DrugBank:
DB00741
PDB:
PDN
ChEBI:
17650
KEGG Compound:
C00735
KEGG Drug:
D00088
PubChem Compound:
5754
PubChem Substance:
3998
46505089
Drugs Product Database (DPD):
2242930
BindingDB:
22476
ChemSpider:
5551
HET:
PDN
Therapeutic Targets Database:
DAP000718
FDA Drug Label at DailyMed:
b221b509-ea5c-427c-94f7-27939957ed97

Clinical Trials

These are trials that mention hydrocortisone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.